Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New triple therapy shows promise in stomach cancer fight

NCT ID NCT04208347

Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the immunotherapy drug camrelizumab to standard chemotherapy and the targeted drug apatinib improves outcomes for people with stomach or gastroesophageal junction cancer that can be surgically removed. About 580 adults will receive the treatment before and after surgery. The goal is to see if this combination leads to more complete tumor disappearance and longer survival without the cancer coming back.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 580 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2019

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has previously untreated localized gastric or GEJ adenocarcinoma as defined by T3-4N+M0; * Plans to proceed to surgery following pre-operative chemotherapy. * Has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1. * Has adequate organ function. * Male participants of childbearing potential must agree to use an adequate method of contraception for the course of the study through 120 days after the last dose of therapy. * Female participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of therapy. * Has life expectancy of greater than 12 months. Exclusion Criteria: * Uncontrolled hypertension ( systolic ≥140 mmHg or diastolic ≥90 mmHg despite antihypertensive therapy) * Known hypersensitivity to any of the study drugs or excipients. * Known hereditary or acquired bleeding and thrombotic tendencies (e.g. hemophiliacs, coagulation disorders, thrombocytopenia, etc.); * Congenital or acquired immune deficiency (e.g. HIV infected)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastric adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adenocarcinoma gastric adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastric and gastroesophageal junction (GEJ) adenocarcinoma

Contacts and locations

Locations

  • Affiliated Hospital of Hebei University

    Baoding, China

  • Affiliated Hospital of Jiangsu University

    Zhenjiang, China

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, China

  • Cancer Hospital of the University of Chinese Academy of Sciences

    Hangzhou, China

  • Changhai Hospital

    Shanghai, China

  • First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, China

  • Hainan Cancer Hospital

    Haikou, China

  • Hefei Cancer Hospital, Chinese Academy of Sciences

    Hefei, China

  • Henan Provincial Cancer Hospital

    Zhengzhou, China

  • Heping Hospital Affiliated to Changzhi Medical College

    Changzhi, China

  • Jilin Guowen Hospital

    Siping, China

  • Lanzhou University Second Hospital

    Lanzhou, China

  • Liaoning Cancer Hospita & Institute

    Shenyang, China

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, China

  • Shanxi Provincial Cancer Hospital

    Taiyuan, China

  • Sichuan Cancer Hospital & Institute

    Chengdu, China

  • Sichuan Provincial People's Hospital

    Chengdu, China

  • Tangdu Hospital

    Xi'an, China

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, China

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, China

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, China

  • Xiangya Hospital Central South University

    Changsha, China

  • Yantai Yuhuangding Hospital

    Yantai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.